Susquehanna Fundamental Investments LLC Acquires New Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Susquehanna Fundamental Investments LLC purchased a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 169,479 shares of the biotechnology company's stock, valued at approximately $11,140,000. Susquehanna Fundamental Investments LLC owned approximately 0.09% of BioMarin Pharmaceutical as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new stake in BioMarin Pharmaceutical during the 3rd quarter valued at $809,000. Tidal Investments LLC increased its position in shares of BioMarin Pharmaceutical by 150.4% during the third quarter. Tidal Investments LLC now owns 30,467 shares of the biotechnology company's stock worth $2,142,000 after acquiring an additional 18,300 shares in the last quarter. Synovus Financial Corp raised its holdings in shares of BioMarin Pharmaceutical by 25.7% in the 3rd quarter. Synovus Financial Corp now owns 30,253 shares of the biotechnology company's stock worth $2,127,000 after acquiring an additional 6,191 shares during the last quarter. GAMMA Investing LLC lifted its position in BioMarin Pharmaceutical by 57.5% in the 4th quarter. GAMMA Investing LLC now owns 1,232 shares of the biotechnology company's stock valued at $81,000 after acquiring an additional 450 shares in the last quarter. Finally, Everence Capital Management Inc. acquired a new position in BioMarin Pharmaceutical during the 4th quarter valued at about $333,000. Institutional investors and hedge funds own 98.71% of the company's stock.

Insider Buying and Selling at BioMarin Pharmaceutical

In other news, CAO Erin Burkhart sold 1,295 shares of the firm's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total value of $92,618.40. Following the completion of the transaction, the chief accounting officer now directly owns 16,955 shares in the company, valued at approximately $1,212,621.60. This trade represents a 7.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.85% of the company's stock.

BioMarin Pharmaceutical Stock Performance

Shares of NASDAQ BMRN traded down $0.68 during midday trading on Friday, hitting $62.03. The company's stock had a trading volume of 1,151,024 shares, compared to its average volume of 1,855,952. The firm has a market capitalization of $11.84 billion, a price-to-earnings ratio of 28.21, a P/E/G ratio of 0.61 and a beta of 0.30. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. The stock has a fifty day moving average price of $66.03 and a 200 day moving average price of $65.83. BioMarin Pharmaceutical Inc. has a one year low of $52.93 and a one year high of $94.85.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.54 by $0.18. The firm had revenue of $747.31 million for the quarter, compared to the consensus estimate of $711.05 million. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. On average, research analysts forecast that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current fiscal year.

Analysts Set New Price Targets

BMRN has been the topic of a number of recent research reports. Royal Bank of Canada restated a "sector perform" rating and issued a $70.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Wedbush restated an "outperform" rating and set a $94.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Scotiabank upped their target price on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the stock a "sector perform" rating in a research note on Thursday, February 20th. Citigroup raised their price target on shares of BioMarin Pharmaceutical from $81.00 to $82.00 and gave the company a "neutral" rating in a research report on Thursday, February 20th. Finally, Oppenheimer upgraded shares of BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 price target on the stock in a report on Monday, February 24th. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $93.14.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.